User reviews

User Review - Flag as inappropriate

Cytokinetics Post Ispinesib; clinical trial data
(CYTK) 4.86: Company published ongoing I / II stage <a href="">Ispinesib</a>; clinical trial
data, the first stage was found that the best response rate was three patients functional damage reduced by 30% or more in diameter, where a tumor appeared local reactions, three patients after four months or longer periods in stable condition. The most common side effects were neutropenia syndrome, accounting for 85%.
Medchemexpress Can provide the above product,its website:<a href=""></a>
<a href="">VX-745</a>
<a href="">TAK-715</a>
<a href="">SB 239063</a>
<a href="">SD-06</a>
<a href="">Vinorelbine</a>
<a href="">LY2228820</a>
<a href="">PD0325901</a>
<a href="">Trametinib</a>
<a href="">GSK1120212 DMSO solvate</a>
<a href="">PD98059</a>

All reviews - 1
5 stars - 0
4 stars - 0
3 stars - 0
2 stars - 0
1 star - 0

All reviews - 1
Editorial reviews - 0